Vitamin D, a secosteroid predominately obtained by endogenous production, has in recent years been linked to obesity and its comorbidities. The purpose of this review is to draw conclusions from animal and human studies on the effects of vitamin D on adipogenesis to identify the molecular links between vitamin D and obesity. The information presented herein was obtained from 4 databases (PubMed, CINAHL, Cochrane Library, Scopus) using predefined search terms, as well as research literature and other reviews. The effects of vitamin D on adipogenesis have been researched in several animal models, and the majority of these studies suggest vitamin D plays an inhibitory role in adipogenesis. Studies into vitamin D status and obesity in humans are limited, with the majority being observational epidemiological studies that provide no conclusions on cause and effect or clear links on the molecular mechanisms. The few cell culture and supplementation studies that have investigated adipogenesis in human cells indicate that, in contrast to findings from rodent studies, vitamin D is proadipogenic. There is insufficient evidence to determine whether 1) vitamin D deficiency is associated with a lean or obese phenotype, 2) vitamin D deficiency is a consequence of obesity, or (3) the effects of vitamin D on fat tissue are due to interactions with calcium.
INTRODUCTION
The obesity epidemic affects an estimated 39% of the global adult population. 1 Vitamin D (VitD) deficiency is also a worldwide health issue. 2, 3 In Australia, deficiency (25- 
hydroxyvitamin D [25(OH)D] <50 nmol/L)
affects approximately 6% of the population in summer and approximately 49% of the population in winter. 4 In the United States, approximately 32% of the population is classified as deficient. 5 Low VitD status is inversely correlated with obesity measures 6 ; however, it is unclear whether VitD deficiency is a cause or an outcome of obesity. Strengthening the link between the two are associations between VitD deficiency and many comorbidities of obesity. [7] [8] [9] [10] Fat-soluble VitD is stored in adipose tissue, 11 and the enzymes required to produce the active form of VitD are expressed within the tissue, 12 suggesting both autocrine and paracrine functions. Understanding the effects of VitD on adipocyte function may help identify causal links between obesity and VitD. Studies into the effects of VitD on adipogenesis and adipocyte function have been conducted in several animal models. The most commonly used model is 3T3-L1 mouse preadipocytes, with results from studies of this model suggesting VitD has an antiadipogenic effect. [13] [14] [15] [16] Interestingly, the results of many of these studies conflict with the results from human adipocyte studies, which suggest a proadipogenic effect of VitD, if any, including increased adipocyte proliferation and lipogenesis, with VitD potentially working in concert with calcium. [17] [18] [19] [20] [21] Thus, there is a potential effect of species on the effect of VitD on adipogenesis and adipocyte function. Human VitD supplementation trials found conflicting effects of VitD on body mass index (BMI), body weight, body composition, and waist circumference, 22, 23 whereas observational studies showed a strong link between low VitD status and obesity. [24] [25] [26] [27] This review outlines the research to date on the metabolism and storage of VitD in adipose tissue and the effects of VitD on adipogenesis. First, VitD metabolism and adipogenesis are briefly explained. Second, the storage of VitD in adipose tissue and the expression of the VitD metabolizing enzymes are discussed. Last, the effects of VitD on adipogenesis are considered, with conflicting observations highlighted.
VITAMIN D
Vitamin D refers to a group of fat-soluble secosteroids. Of the 5 forms, only vitamin D 2 (VitD 2 ) and vitamin D 3 (VitD 3 ) are physiologically important in the human body. Classical physiological roles for VitD include calcium homeostasis and bone metabolism, 28 but a more varied role for VitD has been identified. 29, 30 The majority of VitD 3 is made endogenously and involves systematic hydroxylation of the metabolites for it to reach its bioactive form ( Figure 1 ). The process starts in the skin where exposure to a specific range of UVB rays (280-315 nm) causes 7-dehydrocholesterol to be converted to preVitD 3 . Isomerization then converts pre-VitD 3 into VitD 3 . Vitamin D 2 and a small amount of VitD 3 are found in dietary sources and are absorbed in the small intestine through passive diffusion and cholesterol transporters. Vitamin D exerts genomic effects, including regulating bone mass 32 and intestinal calcium uptake 33 and increasing expression of tumor suppressors p53 and p21 34 through the binding of 1,25(OH) 2 D to the VitD nuclear receptor (nVDR). Vitamin D also exerts nongenomic effects, including expression of mitogenactivated protein kinase in muscle tissue 35 and rapid calcium absorption, 36 through the binding of 1,25(OH) 2 D to the VitD membrane receptor. Vitamin D is crucial for bone metabolism and development, and levels of 1,25(OH) 2 D are affected by calcium, phosphate, and parathyroid hormone. 37 Several extrarenal tissues, including adipose tissue, have the enzymes necessary to produce 1,25(OH) 2 D. 38 Recent studies have identified a wide range of target genes for VitD throughout the human body, [39] [40] [41] [42] which is not surprising considering the large number of gene targets for other nuclear receptors.
ADIPOSE TISSUE
Adipocytes arise from multipotent mesodermal stem cells (MSCs) found in the adipose tissue stroma. 43 Differentiation of MSCs to mature adipocytes is achieved in 2 phases ( Figure 2A) ; the first phase is called determination and involves the commitment of MSCs to becoming preadipocytes. Preadipocytes are fibroblasts that can be stimulated to differentiate into adipocytes. 44 The second phase is terminal differentiation, in which preadipocytes become mature adipocytes. There are 2 main types of adipose tissue; white adipose tissue (WAT) is predominantly for storage of fatty acids, and brown adipose tissue (BAT) functions to dissipate energy through generating heat. 45 Obesity is caused by an energy imbalance, where energy intake exceeds energy use. The imbalance leads to expansion of WAT through hyperplasia and hypertrophy of adipocytes.
Subcutaneous adipose tissue (SAT) refers to the adipose tissue found in the hypodermis under the skin. 46 Visceral adipose tissue (VAT) refers to the adipose tissue found around organs in the abdominal cavity. 47 In obesity there is hypertrophy of the adipocytes found in VAT; this increase in size is linked to increases in proinflammatory cytokine production and release. 47 The dysfunctional behavior of VAT in obesity is suggested to be a major factor in the development of insulin resistance and the metabolic syndrome. [48] [49] [50] The influence of SAT functioning in obesity and on the development of these comorbidities is not as well researched or defined. There is research to suggest that SAT may also contribute to insulin resistance and the metabolic syndrome through proinflammatory actions, altered fatty-acid metabolism, adipocyte hypertrophy, and reduced capacity for angiogenesis. 51 
Adipogenesis
Adipogenesis involves a cascade of interactions among many signaling molecules ( Figure 2B ). The main components of the adipogenesis-signaling pathway are the CCAAT enhancer binding proteins (C/EBP) and peroxisome proliferator-activated receptor gamma (PPARc). Activated PPARc heterodimerizes with retinoid Â receptor 52 and upregulates the expression of genes involved in lipid storage and adipogenesis. 53 Of the 6 C/EBP isoforms, C/EBPa, b, and d promote adipogenesis. 45 C/EBPb and C/EBPd are induced in the early stages of adipogenesis and together induce expression of C/EBPa. 45 C/EBPa and PPARc are the major regulators of adipogenesis and positively feedback onto their own and each others' production. 54 Many transcription factors influence the expression of these 2 major players. Positive effectors include signal transducer and activator of transcription 5 (STAT5), sterol regulatory element binding transcription factor 1c (SREBP1c), C/EBPm, and krupple-like protein (KLF) 5 and 15. Negative effectors include C/EBP homologous protein (CHOP), KLF2 and 7, and wingless type MMTV integration site 10 b (Wnt10b). 45 
VITAMIN D AND ADIPOSE TISSUE
Vitamin D status is assessed by serum levels of 25(OH)D. No consensus on the definition of deficiency exists, but generally insufficiency is defined as < 50 nmol/L, 55, 56 although different conditions have been assigned different cutoffs. 29, 57 Vitamin D insufficiency is common in individuals with obesity, and although the exact relationship between obesity and VitD status has not been identified, many theories have been postulated. [58] [59] [60] [61] The majority of studies linking obesity and VitD deficiency in humans are observational studies and suggest a range of associations, including links between variations in the genes that encode proteins for the DBP and nVDR. [62] [63] [64] Adipose tissue is a storage site for fat-soluble VitD, 11, 60 and high levels of VitD have been found in the adipose tissue of obese persons, despite these persons being considered VitD deficient as a result of blood testing of 25(OH)D. 65, 66 The exact mechanism by which adipose tissue "holds" VitD bound is unknown, and there are conflicting reports on the effects of weight loss on serum and adipose tissue levels of VitD. [66] [67] [68] Vitamin D storage in human adipose tissue Cholecalciferol (Vitamin D 3 ) is the predominant VitD metabolite found in adipose tissue. 60 The cytochrome P450 enzymes (CYP2R1, CYP27A1, CYP27B1, CYP24A1) responsible for the production and catabolism of 1,25(OH) 2 D are found in adipose tissue. 69 A few studies have used liquid chromatography with mass spectrometry to detect VitD 2 and VitD 3 content in adipose tissue. 11, 65, 66, 70 Adipose tissue levels of VitD 2 are undetectable or detected at very low levels, whereas VitD 3 is readily detected in various adipose sites. 11, 65, 66, 70 At an individual level, both VitD 3 and VitD 2 are not evenly distributed across the various fat sites, with a wide range of levels across all samples. 66 There are conflicting results regarding correlation between serum 25(OH)D and SAT content of VitD 3 or 25(OH)D in individuals with obesity, with some studies finding positive associations 11, 68, 70 and others no correlation. 65, 66 One study measured VitD 2 and VitD 3 in SAT and VAT of obese and lean individuals. 11 No difference was found between total VitD in SAT or VAT for lean or obese groups, but the obese group had significantly higher total body VitD stores than the lean group, p <0.01.
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Vitamin D metabolism in human adipose tissue
The vitamin D receptor (VDR) and VitD metabolizing enzymes for the production of 25(OH)D and 1,25(OH) 2 D are expressed in human adipose tissue. Wamberg et al. 12 investigated associations between serum 25(OH)D and the expression levels of VitD metabolizing enzymes in SAT and VAT from 20 lean and 20 obese individuals. In all individuals, the 25-hydroxylase enzyme CYP27A1 expression was higher in VAT compared with SAT. 12 Expression levels of CYP2J2, another 25-hydroxylase enzyme, were highest in the SAT of lean individuals but comparable in all other samples. 12 The 1a-hydroxylase enzyme CYP27B1 was also highest in the SAT of lean individuals and comparable in all other samples. 12 These data suggest that production of the 25(OH)D and 1,25(OH) 2 D may be downregulated in the SAT of obese individuals due to lower expression of CYP2J2 and CYP27B1. There were no differences in the expression of degrading enzyme CYP24A1 among adipose tissue sites or groups, 12 suggesting that any variation in VitD metabolism due to weight or fat depot is related to the production of the active metabolite and not the catabolism.
The location of the enzymes in the adipose tissue provides an indication of where VitD metabolism may occur. Expression of CYP27A1 and CYP27B1 is reportedly higher in the stromal vascular fraction (SVF) compared with isolated mature adipocytes. 12 Nimitphong et al. 17 also measured the expression of several VitD metabolizing enzymes in cultured human adipocytes. In agreement with the results from Wamberg et al. 12 CYP27B1 and VDR mRNA were detected in VAT and SAT, with levels higher in the SVF compared with the mature adipocytes. 17 The SVF contains a range of cells, including macrophages and mesenchymal stem cells, which are reported to produce 1a-hydroxylase. 71, 72 This suggests that the majority of VitD metabolism in established adipose tissue may occur in preadipocytes and the components of the SVF, rather than mature adipocytes.
Cell culture of human adipocytes showed that dosing the adipocytes with 1,25(OH) 2 D or 25(OH)D increased expression of CYP24A1 in both preadipocytes and newly differentiated adipocytes, 17 suggesting VitD may regulate its own production, as is the case in keratinocytes. 73 Similar results were shown in a study investigating serum 25(OH)D levels and expression levels of VitD metabolizing enzymes in SAT before and after a 12-week low-calorie diet intervention. This suggests that this enzyme is upregulated during weight loss achieved by lifestyle interventions, potentially to breakdown the excess VitD released from adipose tissue.
Few studies have investigated the expression of VDR in human adipocytes. Microarray studies have shown that human adipocytes express VDR 74 and macrophage inflammation induces expression of VDR in adipose tissue. 75, 76 One study showed a significantly higher expression of VDR in the SAT of lean individuals compared with the VAT (p ¼ 0.0002) but comparable expression between the SAT and VAT of individuals with obesity. 12 However, significantly more VDR was expressed in VAT from individuals with obesity compared with lean individuals (p ¼ 0.01), 12 suggesting VAT may use VitD more in individuals with obesity.
Vitamin D metabolism in mouse adipose tissue
In animal models, VDR and CYP24A1 has been found to be expressed in adipose tissue. 14, [77] [78] [79] [80] This effect is dose and time dependent 13, 16, 85, 86, 87 because it is only seen in the early stages of adipogenesis 13 ,84 and appears to occur through several pathways.
Vitamin D suppresses adipogenesis by inhibiting expression of C/EBPa, PPARc, [13] [14] [15] [16] 83, 84, 87 C/EBPb, 14 and adipocyte protein 2 (AP2). 13, 15, 17 During terminal differentiation, there is a cascade of transcriptional events, whereby C/EBPb and C/EBPd induce expression of C/EBPa and PPARc, leading to terminal differentiation of preadipocytes.
89 AP2 or fatty acid binding protein 4 is a carrier protein for fatty acids produced by adipose tissue and macrophages, which translocates ligands, i.e., fatty acids, to the PPARc receptor in the nucleus and enhances its transcriptional activity. 90 Inhibition of these pathways suggests a role for VitD in suppressing terminal differentiation of 3T3-L1 adipocytes.
Vitamin D also upregulates expression of a myeloid translocation protein, eight-twentyone (ETO).
14 ETO is a C/EBPb corepressor 91 and maintains expression of WNT10b, which inhibits PPARc expression. 83 WNT10b is a member of the Wnt family and is expressed in adipose tissue. The Wnt family functions through 2 signaling pathways, a canonical and a noncanonical pathway. 92 The canonical pathway protects b-catenin from ubiquitination, allowing b-catenin to translocate to the nucleus and initiate transcription of genes, including PPARd, which inhibits PPARc expression. 93 During adipogenesis, Wnt signaling is downregulated, but 1,25(OH) 2 D has been found to maintain the Wnt signaling pathway and exert antiadipogenic effects in 3T3-L1 cells. 83 In 3T3-L1 preadipocytes, C/EBPb has been shown to regulate Wnt10b expression, which supresses the antiadipogenic effects of the Wnt/b-catenin pathway. 94 Vitamin D suppression of C/EBPb may be overriding this regulation and maintaining the Wnt pathway.
Vitamin D decreases lipid accumulation by suppressing expression of SREBP1c 13 and lipoprotein lipase (LPL). 13, 83 SREBP1c induces the expression of transcription factors that promote the expression of genes involved in glucose metabolism, lipogenesis, and fattyacid production. 95, 96 A functional 1,25(OH) 2 D response element has been found in the promoter region of the Insig2a gene, which encodes a protein that blocks the processing of SREBPs. This suggests that 1,25(OH) 2 D may regulate SREBP1c expression via Insig2. 97 Additionally, C/EBPb and C/EBPa have been shown to stimulate SREBP1c expression 98 ; therefore, VitD may also be regulating SREBP1c via inhibition of this pathway. Lipoprotein lipase is involved in the hydrolysis of triglycerides from lipoproteins, the movement of lipids, and the mediation of lipoprotein-free uptake of lipids and fat-soluble vitamins. 99 Lipoprotein lipase is a marker of adipocyte differentiation and increases with triglyceride accumulation. 99 In 3T3-L1 cells, LPL expression is inhibited by 1,25(OH) 2 D, leading to reduced lipid accumulation. 13, 83 Additionally, there is evidence of 1,25(OH) 2 D influencing triglyceride accumulation in 3T3-L1 mouse preadipocytes. 16, [81] [82] [83] [84] [86] [87] [88] Most studies found a greater decrease in lipid accumulation with increasing doses of 1,25(OH) 2 D. However, one study showed low doses of 1,25(OH) 2 D (10 À8 M) stimulated triglyceride accumulation, but higher doses (10 À6 M) inhibited accumulation. 82 There is also some evidence that the VDR itself is able to influence adipogenesis, with unliganded VDR shown to promote adipogenesis in the 3T3-L1 cell line through increased lipid accumulation. 55, 101 The difference in results among these studies could be due to differences in treatment periods, cell types, and/or VitD treatment protocols.
Vitamin D in mouse models
Mouse models have been used to investigate the effects of vitamin D supplementation on body composition and expression of a range of factors involved in adipogenesis.
Mice fed an AIN93G diet containing 0.25 lg/kg of VitD 3 (10 times the rodent requirement) have significantly increased SAT (p ¼ 0.032) and VAT (p ¼ 0.043) compared with mice fed an AIN93G diet containing 0.025 lg/kg of VitD 3 (the rodent requirement), in the absence of any significant difference in body weight. 106 This dose is 10 times the recommendation for a rodent and suggests that supplementation at this level leads to a proadipogenic state. This data are in contrast with the results seen in 3T3-L1 cell culture studies, suggesting there are substantial systemic influences on this process that are missed by in vitro studies. Conversely, when minipumps were used to provide a continuous dose of 1,25(OH) 2 D (18 pmol/d) to SAM-P/6 mice for 6 weeks significantly decreased adiposity and PPARc mRNA expression was observed (p < 0.001), 107 suggesting an inhibitory effect on adipogenesis and offering further evidence that PPARc inhibition is the mechanism by which 1,25(OH) 2 D inhibits adipogenesis. This method of treatment overrides the normal process for 1,25(OH) 2 D production by directly providing the active form of VitD, potentially leading to a much higher level of active VitD than that achieved through VitD supplementation.
There is some evidence that VitD and calcium work together to influence energy metabolism and adipogenesis. Using a model of diet-induced obesity, mice fed a high-fat diet supplemented with both calcium (1.2% calcium) and VitD (0.025 lg/kg plus an additional 0.625 lg/d) showed lower terminal body weight, reduced weight gain, and lower total WAT, in comparison with diet-induced obese mice on standard chow (0.6% calcium, 0.025 lg/kg VitD), 108 although mice on diets supplemented with either VitD (0.025 lg/kg plus an additional 0.625 lg/d) or calcium (1.2% calcium) alone trended toward a lower terminal body weight compared with diet-induced obese mice on standard chow (0.6% calcium, 0.025 lg/kg VitD). 108 Calcium and VitD, both separately and in combination, significantly increased WAT apoptosis (p < 0.05). 108 The authors hypothesized that VitD-induced activation of calciummediated apoptosis pathways is responsible for the antiadipogenic effects of the supplemented diets. 108 Perhaps the main difference in outcomes between the in vitro and in vivo studies is due to the involvement of the calcium-mediated apoptosis pathway. This emphasizes the necessity of examing the effects of nutrients in vivo, rather than rely on mechanisms derived in vitro. VDR À/À mice provide an interesting insight into the relationship between VitD and obesity. VDR À/À mice present with a lean phenotype, whereas mice overexpressing VDR (VDR þ ) present with an obese phenotype. [109] [110] [111] [112] In contrast with the majority of animal studies, the VDR À/À model suggests VitD has a stimulatory effect on adipogenesis. VDR À/À mice exhibit higher food intake 110, 111 and have lower total adipose tissue mass but the same amount of brown adipose tissue (BAT) as wild-type littermates. 110 112 This suggests VitD may directly influence leptin regulation and exert its effects on energy metabolism through leptin.
In summary, VDR À/À mice had lower total adipose tissue mass with a higher proportion of BAT compared with wild-type mice, as well as WAT with characteristics of BAT. Food intake is also higher in this model, which may be due to increased energy use from higher amounts of BAT.
Vitamin D in rat models
Few studies have investigated the effects of VitD on adipogenesis in rat models. 115 Vitamin D was only effective at stimulating adipocyte differentiation when added during the initial growth stage (1-5 d) . 115 Rats fed a Vitamin D-deficient diet for 12 weeks displayed lower body weight, body fat, visceral adiposity, and triglyceride mass compared with rats on a VitD-sufficient diet (0.025 lg/kg). 116 Interestingly, these rats also had higher adipocyte numbers compared with control animals, suggesting that VitD promotes differentiation of adipocytes from existing progenitor cells but supresses further cell proliferation. Vitamin Ddeficient diets also led to decreased expression of proadipogenic factors Leptin, fatty-acid synthase (FASN), and PPARc and increased expression of UCP1 and UCP2. 116 Vitamin D works in concert with calcium to regulate calcium homeostasis, keratinocyte growth, parathyroid hormone levels, and bone metabolism. 28, 117 Calcium also influences adiposity. 18, 118 A high calcium rescue diet given to rats fed a VitD-deficient diet increased body weight, fat mass, and visceral adiposity. The calcium diet partially rescued the expression of PPARc, FASN, and Leptin and completely rescued UCP expression to that of the controls. 116 These studies suggest VitD has a stimulatory effect on adipogenesis in rat progenitor cells and mature adipocytes and that the interplay of calcium and VitD appears to be important in adipocyte development.
Vitamin D in porcine models
Bone marrow stromal cells from pigs treated with either 10 À8 M or 10 À7 M 1,25(OH) 2 D for 12 days displayed reduced proliferation and increased lipid accumulation in comparison with untreated cells, suggesting increased differentiation to adipocytes. 119 Treatment with 1,25(OH) 2 D also increased expression of PPARc, LPL, and AP2 in a dose-dependent manner. 119 Mature adipocytes from porcine SAT treated with 10 À11 M to 10
À7
M of 1,25(OH) 2 D also showed a dose-and timedependent decrease in cell proliferation. 120 Vitamin D treatment also suppressed expression of adipogenic genes LPL, phosphoenolpyruvate carboxykinase, steroyl-CoA desaturase, glucose transporter type 4, and GPDH (a marker of mature adipocytes) in the mature adipocytes. 120 The GPDH gene is expressed in mature adipocytes and is used as a marker of adipogenesis. GPDH activity was significantly decreased (p < 0.05) and lipid accumulation was lower in porcine adipocytes treated with 1,25(OH) 2 D, in a dose-dependent manner. 120 These studies suggest VitD has a stimulatory effect on adipogenesis in porcine progenitor cells but an inhibitory effect in mature adipocytes.
Vitamin D in human epidemiology
A large number of studies have been conducted to ascertain the association between VitD and obesity. The majority of these studies are observational studies and compare anthropometric measures with serum 25(OH)D. The overall results show an association between lower VitD status and higher body weight, BMI, and fat mass. [25] [26] [27] [121] [122] [123] [124] Lower VitD status has been linked to new onset of obesity in adults, 24 and this appears to be bidirectional, with low VitD status increasing the risk of obesity and obesity lowering VitD status.
The findings from epidemiological studies cannot be used to conclude whether low VitD status is a cause or consequence of obesity, but there are several theories on the link between them. The sequestration theory suggests that in weight-stable obese individuals, fatsoluble VitD is stored and trapped in adipose tissue, leading to lower amounts of 25(OH)D being produced and released into the blood, 60 thereby limiting the 25(OH)D available in the blood and indicating a lower VitD status. Recent research has shown a similar concentration of VitD in both SAT and VAT of obese and lean individuals but higher total stores of VitD in individuals with obesity. 11 It would be expected that these stores would be released during weight loss and potentially increase 25(OH)D levels, although there is conflicting evidence to support this in the literature. [66] [67] [68] Reduced sun exposure and potential differences in VitD synthesis and release from the skin in individuals with obesity have been investigated. 61 Findings suggest that weight does not affect an individual's production of VitD 3 , but individuals with obesity may have impaired release of VitD 3 from the skin. 61 Diseases of the liver and kidneys associated with obesity, such as nonalcoholic fatty liver disease and chronic kidney disease from diabetes or hypertension, also influence VitD status and function. 9, 125 Another theory is that volumetric dilution can explain the majority of differences in serum 25(OH)D levels between obese and lean individuals. 58 The authors suggest that the inverse association between serum 25(OH)D levels and body size is related to the larger volume for distribution of VitD and 25(OH)D in the tissue mass of individuals with obesity compared with lean individuals. 58 Vitamin D in human primary cell culture studies
In contrast with the results from the majority of animal cell cultures, studies using human adipocytes have shown increased adipocyte differentiation and lipid accumulation when treated with VitD. Interestingly, VDR has potential unliganded effects in human adipose tissue. In brown adipose tissue, unliganded VDR decreases expression of UCP1, which is required for non-shivering thermogenesis. 126 This suggests that VDR may modulate fat metabolism by inhibiting expresson of UCP1 in a ligand-independent manner.
As previously mentioned, calcium and VitD appear to work together to influence adipogenesis. Research has shown that increasing intracellular calcium in human adipocytes promotes energy storage and accumulation of lipids by stimulating de novo lipogenesis and inhibiting lipolysis. [127] [128] [129] Vitamin D increases intracellular calcium in adipocytes via a 1,25(OH) 2 D membrane-associated rapid response to steroid-binding protein (1,25(OH) 2 D-MARRS). 21, 130 This leads to a nongenomic VitD-mediated increase in lipogenesis and decrease in lipolysis. Additionally, it has been reported that VitD-mediated increases in intracellular calcium leads to increased angiotensin II cortisol release from adipocytes. 20 Dysregulated glucocorticoid metabolism has been suggested as a possible regulator of adipose tissue mass and deposition (ie, increased visceral fat) and could be a potential mechanism for VitD and calcium in development of central obesity. 20 Additionally, 1,25(OH) 2 D has been reported to inhibit expression of UCP2 via its nuclear receptor. 131 This suggests that VitD influences human adipocyte lipid metabolism and adipogenesis by both genomic and nongenomic mechanisms.
Vitamin D in human intervention studies
A recent systematic review and meta-analysis of all randomized controlled trials investigating the effects of VitD supplementation on body weight and composition, while controlling for calcium intake, suggested that VitD supplementation did not decrease measures of adiposity when no restriction was placed on calorie intake. 22 This suggests VitD supplementation alone may play a small part, if any, in body weight and composition changes. Since the review was published, there have been another 8 randomized controlled trials that fit their selection criteria. Seven studies showed no differences in weight loss, BMI, waist circumference, or other obesity measures between VitD-supplemented groups and placebo groups. [132] [133] [134] [135] [136] [137] [138] The 8th study showed no differences between intervention groups (2000 IU/d vs placebo for 12 mo) when VitD status was analyzed as a mean value but found there was an association between better VitD status and greater decreases in body weight, BMI, trunk fat mass, and body fat percentage when VitD status was broken into tertiles. 139 Although this was only significant for trunk fat mass (p ¼ 0.02) after adjusting for covariates (age, race, baseline BMI, baseline serum 25(OH)D, VitD and calcium intake, and sun exposure). They also found that, when participants were grouped by repletion of VitD status, those who became replete had significantly greater decreases in BMI (p ¼ 0.02), waist circumference (p ¼ 0.03), and hip circumference (p ¼ 0.03). 139 A potential limitation of these studies is the baseline VitD status of participants. Although there is still some debate on the optimal level of 25(OH)D for health, with some research groups suggesting >75 nmol/L for overall health benefits, [140] [141] [142] many advisory bodies are defining insufficiency as serum 25(OH)D levels <50 nmol/ L. 55, 56, 143, 144 All but 2 articles included in the systematic review reported on studies with participants who had mean baseline 25(OH)D levels <75 nmol/L, 145, 146 and another article did not report 25(OH)D levels. 147 The 8 additional articles since the systematic review all reported on studies with participants who had mean baseline serum 25(OH)D levels <75 nmol/L, with 4 reporting mean baseline serum 25(OH)D levels <50 nmol/L. It is possible the null effect of raising serum 25(OH)D levels on these obesity measures could be confounded by the baseline VitD status of participants.
The meta-analysis did not include trials that used different doses of calcium between intervention groups. 22 It is possible that the interplay of calcium and VitD may be able to explain the links in observational studies between obesity and VitD, as evidenced by some rodent studies. 108, 116 In a randomized, doubleblind controlled trial, women undergoing a 15-week weight-loss program were supplemented with both calcium (1200 mg) and VitD (400 IU) or with a placebo. 148 There were no differences in fat mass loss between groups, although, when the analysis was limited to only low dietary calcium consumers, significant decreases in body weight (p ¼ 0.009), fat mass (p ¼ 0.02), and dietary lipid intake (p ¼ 0.02) were seen in the supplemented group. 148 This study suggests calcium may be the component that has the antiadipogenic effect, although it appears to only be effective in those consuming low amounts of dietary calcium. It is also important to note 25(OH)D levels were not reported, so the effect of VitD status cannot be inferred. In another doubleblind, placebo-controlled trial, obese men and women with serum 25(OH)D levels >25 nmol/L underwent a 16-week weight-loss program supplemented with 3 servings a day of orange juice, which either contained a total of 1050 mg calcium and 300 IU VitD per day or no added calcium or VitD. 149 They found no difference in weight loss between groups but did find a significant decrease in VAT in the supplemented group as measured by tomography scans (p ¼ 0.039). 149 The lack of antiadipogenic results in human VitD supplementation trials, compared with both animal cell cultures and interventions, may be due to speciesrelated differences or a tissue-specific effect seen only during early adipogenesis. It is possible that the small number of human supplementation trials that showed reductions in adipose tissue measures are confounded by age and sex, as previously reported by Pathak et al. 22 Additionally, the positive effects could be related to calcium intake, as seen in both animal and human studies. [148] [149] [150] [151] Finally, it is possible that in vivo studies using low doses of VitD supplementation for short durations are not sufficient for increasing 25(OH)D to a level that affects adipogenesis. Minimum recommended doses for improving serum 25(OH)D levels range from 400 IU/ day to 2000 IU/day for adults. 55, 144 Differences in VitD doses, duration of intervention, and the baseline VitD status of individuals may influence the results of human VitD supplementation trials on markers of adipogenesis and obesity.
CONCLUSION
The link between obesity and VitD has been suggested through not only observational human studies but also cell culture, animal, and human intervention studies. Despite these links, there is still insufficient evidence to determine whether 1) VitD deficiency is associated with a lean or obese phenotype, 2) VitD deficiency is a consequence of obesity, or 3) the effects of ViD on fat tissue are due to interactions with calcium. It is clear that VitD plays a role in the molecular processes of adipogenesis; however, investigation of the in vitro and in vivo animal and human studies provides no clear indication of the molecular mechanism behind these effects. Murine studies show a stimulatory effect of VitD on adipogenesis, but human primary cell culture suggests an inhibitory effect. Other animal studies provide conflicting results but identify a potential explanation, through differing effects of VitD dependent on the stage of cell maturation. Human supplementation trials provide no clear evidence of the effects of VitD on obesity measures such as BMI, body weight, or body composition. Further, different vitamin D effects on adipogenesis between lean and obese individuals are yet to be elicited. The involvement of calcium in adipose tissue function should be considered a major factor in VitD interaction with adipogenesis and may explain some of the differences between in vitro and in vivo studies. Additionally, these studies only provide information on the effects of exogenously produced vitamin D. Focusing on how to increase endogenous production of VitD instead of supplementation may be the next step in identifying the role of VitD in obesity.
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